Structural basis of the mechanism and inhibition of a human ceramide synthase
Nature Structural & Molecular Biology · 2025-03 · 32 (3) · 431-440
DOI: 10.1038/s41594-024-01414-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Structural & Molecular Biology, online erschienen am 11.11.2024. Verfasst von Tomas C Pascoa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK. tomas.pascoa@cmd.ox.ac.uk. Hauptthemen laut MEDLINE: Oxidoreductases, Membrane Proteins, Sphingosine N-Acyltransferase. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ceramides are bioactive sphingolipids crucial for regulating cellular metabolism. Ceramides and dihydroceramides are synthesized by six ceramide synthase (CerS) enzymes, each with specificity for different acyl-CoA substrates. Ceramide with a 16-carbon acyl chain (C16 ceramide) has been implicated in obesity, insulin resistance and liver disease and the C16 ceramide-synthesizing CerS6 is regarded as an attractive drug target for obesity-associated disease. Despite their importance, the molecular mechanism underlying ceramide synthesis by CerS enzymes remains poorly understood. Here we report cryo-electron microscopy structures of human CerS6, capturing covalent intermediate and product-bound states. These structures, along with biochemical characterization, reveal that CerS catalysis proceeds through a ping-pong reaction mechanism involving a covalent acyl–enzyme intermediate. Notably, the product-bound structure was obtained upon reaction with the mycotoxin fumonisin B1, yielding insights into its inhibition of CerS. These results provide a framework for understanding CerS function, selectivity and inhibition and open routes for future drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK. tomas.pascoa@cmd.ox.ac.uk.
- Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Boehringer Ingelheim Pharma, GmbH & Co. KG, Biberach, Germany.
- Membrane Protein Laboratory, Research Complex at Harwell, Diamond Light Source, Ltd., Harwell Science and Innovation Campus, Didcot, UK.
- Institute of Parasitology, Vetsuisse and Medical Faculty, University of Zürich, Zürich, Switzerland.
- Nanobody Service Facility, University of Zürich, AgroVet-Strickhof, Lindau, Switzerland.
Zitieren
APA
Pascoa, T. C., Pike, A. C. W., Tautermann, C. S., Chi, G., Traub, M., Quigley, A., Chalk, R., Štefanić, S., Thamm, S., Pautsch, A., Carpenter, E. P., Schnapp, G., & Sauer, D. B. (2025). Structural basis of the mechanism and inhibition of a human ceramide synthase. Nature Structural & Molecular Biology, 32(3), 431-440. https://doi.org/10.1038/s41594-024-01414-3
Vancouver
Pascoa TC, Pike ACW, Tautermann CS, Chi G, Traub M, Quigley A, et al. Structural basis of the mechanism and inhibition of a human ceramide synthase. Nature Structural & Molecular Biology. 2025;32(3):431-440. doi:10.1038/s41594-024-01414-3
BibTeX
@article{Pascoa2025,
author = {Pascoa, Tomas C and Pike, Ashley C W and Tautermann, Christofer S and Chi, Gamma and Traub, Michael and Quigley, Andrew and Chalk, Rod and Štefanić, Saša and Thamm, Sven and Pautsch, Alexander and Carpenter, Elisabeth P and Schnapp, Gisela and Sauer, David B},
title = {Structural basis of the mechanism and inhibition of a human ceramide synthase},
journal = {Nature Structural & Molecular Biology},
year = {2025},
volume = {32},
number = {3},
pages = {431--440},
doi = {10.1038/s41594-024-01414-3}
}
EUVIMED